report solid updat guidanc
report adj ep vs opco/street estim
guidanc adj result exclud amort
loss divestitur acqa/integr cost
store-ration off-set tax result top expect due
larg out-performance aetna vs opco/street
mbr top follow quarter tweak
ep guidanc impli guidanc
vs opco/street prior manag also suggest would
grow low-singl digit base ex-item impli next year
opco/street due quarter/outlook tweak
estim
recap segment adj oper incom follow healthcar benefit
flow oper prior quarter ytd
expect vs opco/street though busi
includ net realiz gains/favor note
improv pocket pressur lower-end commerci
middle-market busi recogn last quarter manag still expect
higher end mbr guidanc rang
guidanc follow quarter tweak ep guidanc
impli guidanc vs opco/
street prior increas concentr pharmaci
segment full-year earn project
previous busi stronger
expect claim momentum year
commentari also suggest would grow low-singl digit
ep base exclud pprd/realiz gain impli
ep next year consist prior comment though opco/
street prior compani also increas pbm sell season
outlook due higher gross-new-busi
conclus overal continu move busi forward strong
quarter also seem well posit outperform modest expect
compani continu focu long-term opportun health hub
expect true upsid take time play result maintain perform
year price histori
one nation biggest
retail pharmaci integr one
largest pharmaci benefit manag
analyst certif import disclosur see disclosur
integr aetna line synergi expect
stabil retail/ltc trajectori includ problemat
continu modest growth pbm despit chang
believ long-term outlook could benefit
integr model aetna bring howev expect
take time legaci oper headlin risk like
remain although valuat appear attract histor
level expect move part domin
stori forese futur thu rate share
regulatori chang pharmaci landscap
integr aetna thrive synergi better expect
signific improv retail/ltc trajectori includ
rebound omnicar
improv growth pbm along increas stabil
poor integr aetna synergi wors expect
deterior retail/ltc trajectori continu issu
slow growth pbm worsen regulatori landscap
benefit
product sold
rev
total revenu
net rev
incom tax
dilut ep report
